FDA Drug recall D-1439-2014
Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg
- FDA Drug
- Class III
- terminated
- Published 2014-07-23
On 2014-07-23 the FDA classified a Class III recall of Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg by Teva Pharmaceuticals Usa, citing failed Impurities/Degradation Specifications: out of specification impurity test results.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1439-2014 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2014-06-17 |
| Published | 2014-07-23 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Teva Pharmaceuticals Usa |
| Distribution | US |
Product
Velivet (desogestrel and ethinyl estradiol tablets - triphasic regimen), 0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg, 3 Dispensers x 28 Tablets, Barr Laboratories, Inc., Pomona, NY NDC 0555-9051-67
Reason
Failed Impurities/Degradation Specifications: out of specification impurity test results.
Identifiers
| ndc | 0555-9051-79 |
|---|---|
| ndc | 0555-9051-67 |
| code_info | Lot 33805449A, Exp. 12/14 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1439-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.